Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10151 - 10175 of 10589 in total
Experimental
Matched Iupac: … (2R,3R,4S,5R)-4-{[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}oxane-2,3,5-triol …
Experimental
Matched Iupac: … lambda4-iron(4+) 2-[(E)-{[5-(2-carboxyethyl)-2-[(E)-[(2-oxidophenyl)methylidene]amino]phenyl]imino}methyl …
LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
Investigational
Matched Iupac: … 6-[(2R,5R)-2-methyl-5-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-4-(trifluoromethyl)-1,2-dihydroquinolin …
Ezatiostat is investigated in clinical trials for treating myelodysplastic syndrome. This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen...
Investigational
Matched Iupac: … ethyl (2S)-2-amino-4-{[(1R)-2-(benzylsulfanyl)-1-{[(1R)-2-ethoxy-2-oxo-1-phenylethyl]carbamoyl}ethyl] …
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Iupac: … 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}-1H-pyrazol-4-yl)-2,3,6,7-tetrahydro-1H-purine …
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Matched Iupac: … 3-[(5-chlorothiophen-2-yl)sulfonyl]-1-{4-[6-fluoro-7-(methylamino)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin …
Investigational
Matched Iupac: … (3R)-3-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methyl]-4-hydroxybutyl (2S)-2-amino-3-methylbutanoate …
Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to...
Investigational
Matched Iupac: … 3-(2-methoxyethyl) 5-(2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5 …
Experimental
Vet approved
Matched Iupac: … 2-({4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylphenyl}formamido …
Fedovapagon has been used in trials studying the treatment of Nocturia.
Investigational
Matched Iupac: … (2S)-N2,N2-dimethyl-N1-{[2-methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl]methyl}pyrrolidine …
Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.
Investigational
Matched Iupac: … 1-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-4-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl …
PAC-14028 has been used in trials studying the treatment of Skin Pruritus, Papulopustular Rosacea, and Erythematotelangiectatic Rosacea.
Investigational
Matched Iupac: … (2E)-N-[(1R)-1-(3,5-difluoro-4-methanesulfonamidophenyl)ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin …
Experimental
Matched Iupac: … [(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carbonyloxy] …
Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
Investigational
Matched Iupac: … N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide …
TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis).
Investigational
Matched Iupac: … N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methyl-1H-pyrrolo[3,2-b]pyridine-3- …
Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy).
Investigational
Matched Iupac: … 4-[(N-benzyl-1-{8-chloro-1-methyl-1H,4H-chromeno[4,3-c]pyrazol-3-yl}formamido)methyl]benzoic acid …
Experimental
Matched Iupac: … (4S,6R,9E,11R,12R)-11-{[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy}-4-[(4R) ... -2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.0^{4,6}]trideca-1(13),9-dien-2,7-diyn-12-yl 2-hydroxy-7 …
Experimental
Matched Iupac: … azidooxolan-2-yl]-5-methyl-2-oxo-1,2-dihydropyrimidin-4-olate ... phosphonato}oxy)(oxido)phosphoryl]oxy}(hydroxy)phosphoryl phosphonato)oxy](oxido)phosphoryl}oxy)methyl]-4- …
Experimental
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-{[(9S,10S)-10-hydroxy-9,10-dihydrophenanthren-9- …
Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
Investigational
Matched Iupac: … 4-carbamimidoyl-N-(3-{[(2S)-1-(2,4-dichloro-3-{[(2,4-dimethylquinolin-8-yl)oxy]methyl}benzenesulfonyl …
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of...
Investigational
Matched Iupac: … 2-[(5R)-1-[2-chloro-4-(pyrrolidin-1-yl)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-(propan-2- …
Investigational
Matched Iupac: … (2S,3R,5S)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl (2S)-2-amino-3-methylbutanoate …
CE-224535 has been used in trials studying the treatment of Osteoarthritis.
Investigational
Matched Iupac: … 2-chloro-5-{4-[(2R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-2-yl}-N-[(1 …
AZD9164 has been used in trials studying the basic science and treatment of Chronic Obstructive Pulmonary Disease.
Investigational
Matched Iupac: … (3R)-1-[2-(4-fluorophenyl)ethyl]-3-{[(2S)-2-phenyl-2-(piperidin-1-yl)propanoyl]oxy}-1-azabicyclo[2.2.2 …
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study,...
Investigational
Matched Iupac: … N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl …
Displaying drugs 10151 - 10175 of 10589 in total